Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Achieving sufficient delivery across the blood–brain barrier is a key challenge in the
development of drugs to treat central nervous system (CNS) disorders. This is particularly …

Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

The blood-brain barrier (BBB) constitutes a microvascular network responsible for excluding
most drugs from the brain. Treatment of brain tumors is limited by the impermeability of the …

Focused ultrasound (FUS) is a disruptive medical technology, and its implementation in the
clinic represents the culmination of decades of research. Lying at the convergence of …

For a blood-borne cancer therapeutic agent to be effective, it must cross the blood vessel
wall to reach cancer cells in adequate quantities, and it must overcome the resistance …

Many efforts have been made to achieve targeted delivery of anticancer drugs to enhance
their efficacy and to reduce their adverse effects. These efforts include the development of …

Background Low-intensity pulsed ultrasound with concomitant administration of intravenous
microbubbles (LIPU-MB) can be used to open the blood–brain barrier. We aimed to assess …

The blood-brain barrier (BBB) is a dynamic structure that functions as a gatekeeper,
reflecting the unique requirements of the brain. In this review, following a brief historical …

MR-guided focused ultrasound (MRgFUS) is an emerging technology that can accurately
and transiently permeabilize the blood-brain barrier (BBB) for targeted drug delivery to the …